This review assessed the clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole (MRD) alone or with aspirin (ASA) compared with ASA (and each other, where appropriate) in the prevention of occlusive vascular events in patients with a history of MI or ischaemic stroke/TIA, peripheral arterial disease and multivascular disease.
This review is an update of guidance Technology Appraisal No. 90 (TA90) produced the by National Institute for Health and Clinical Excellence (NICE).